Current obesity treatment guidelines recommend a multifactorial approach to address the range of issues that may contribute to weight regain after medical or surgical weight loss. Recent evidence on available and emerging incretin-based agents shows benefits for individuals at different stages of obesity management, including following bariatric surgery. In fact, the evidence suggests the potential for substantial weight loss with these agents. In this live web broadcast, two obesity experts will discuss weight loss pharmacotherapy in the context of bariatric surgery as part of practical, case-centered sessions, designed to mimic the treatment considerations faced in real-world practice to illustrate how incretin-based agents can be individualized for long-term obesity management and improve patient outcomes.